What changed for Ankylosing Spondylitis
A plain English summary of what recently moved in the public data Voxsanity tracks for Ankylosing Spondylitis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
No tracked figures changed between these two snapshots. Trial and approval data is checked daily, so this page will update when something moves.
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Ankylosing Spondylitis in July 2026. Voxsanity tracks 10 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Ankylosing Spondylitis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04732117 · results posted 30 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04732117) enrolled 137 people in total — 68 received secukinumab and 69 received a placebo (an inactive dummy treatment) — during the first 16-week blinded phase, where neither participants nor their doctors knew who was receiving which treatment. Almost all participants then continued into an open-label phase (where everyone knew what they were receiving) for additional follow-up. The trial was measuring responses in people with ankylosing spondylitis (a type of inflammatory spinal condition) across several standardised s...
-
NCT02557308 · results posted 9 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02557308) enrolled a total of 329 participants across eight treatment groups. The groups included people who stayed on, or switched to or from, one of three types of infliximab-based medicines: Remsima (a biosimilar medicine), Remicade (the original brand), or another anti-TNF medicine (a class of medicines that target a protein involved in inflammation). The trial was primarily tracking specific medical events of concern — such as serious infections, certain types of cancer, liver problems, and serious infusion reactions...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03259074 · results posted 9 March 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03259074) enrolled 859 people with ankylosing spondylitis (a type of inflammatory spinal condition). Participants were divided into three groups: one received a lower dose of the study drug AIN457 (150 mg) for part of the study then switched to placebo, one received a higher dose of AIN457 (300 mg) throughout, and one received a comparator medicine called GP2017 (40 mg). The trial ran for approximately two years (104 weeks) and its main focus was measuring whether participants' spines showed changes on X-ray over that time...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04169373 · results posted 21 September 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04169373) investigated a medicine called upadacitinib (15 mg daily) in people with axial spondyloarthritis — a type of inflammatory condition that mainly affects the spine and joints. The trial was made up of two separate studies running alongside each other. In Study 1, 209 people received a placebo (a dummy pill) and 211 received upadacitinib. In Study 2, 158 received placebo and 156 received upadacitinib. After the first blinded phase, participants moved into an open-label phase (where everyone received the active medic...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04285229 · results posted 28 June 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04285229) enrolled 147 participants who had been diagnosed with radiographic axial spondyloarthritis (a type of inflammatory spinal condition, sometimes called ankylosing spondylitis). Participants were randomly assigned to receive either a placebo (an inactive injection) or a medicine called ixekizumab (80 mg every four weeks). The trial ran in several stages: an initial blinded period where neither participants nor researchers knew who received which treatment, followed by an extended treatment period and a follow-up per...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03178487 · results posted 1 June 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 187 people in total — 94 in a group that started on placebo before switching to upadacitinib 15 mg, and 93 in a group that received upadacitinib 15 mg throughout. The trial was studying upadacitinib, a medicine being investigated for ankylosing spondylitis (a type of inflammatory arthritis affecting the spine). The trial ran in two periods, and the main thing being measured at 14 weeks was whether participants reached a defined level of improvement across four areas: their own rating of disease activity, back pain, ph...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03502616 · results posted 11 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03502616) looked at a medicine called tofacitinib in people with ankylosing spondylitis, a type of inflammatory back condition. A total of 270 people took part — 134 were assigned to receive tofacitinib and 136 were assigned to receive a placebo (a dummy treatment) first, before later switching to tofacitinib. The main thing the trial measured was whether participants reached a meaningful improvement in their disease activity by week 16, using a standard scoring system called ASAS20, which tracks back pain, physical functi...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02552212 · results posted 17 August 2020
According to the results reported on ClinicalTrials.gov, this trial looked at certolizumab pegol (CZP), a medication given by injection, in people with ankylosing spondylitis — a type of inflammatory arthritis affecting the spine. In the first part of the trial (weeks 0 to 52), 158 people received a placebo (a dummy treatment with no active ingredient) and 159 received CZP. After week 52, 243 participants moved into an open-label extension phase (meaning everyone knew they were receiving CZP) that ran through to week 156. The trial measured things like disease activity scores, pain, stiffness,...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02696031 · results posted 7 August 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02696031) enrolled 555 adults across three groups in its main phase: 185 received secukinumab with a loading dose schedule, 184 received secukinumab without a loading dose, and 186 received a placebo (an inactive treatment). A further 372 participants continued into a longer extension phase lasting up to around four years. The trial was measuring responses in people with ankylosing spondylitis (a type of inflammatory spinal condition) using a standard scoring system called ASAS — a set of measures that tracks things like b...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02509026 · results posted 16 June 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02509026) enrolled 210 people with ankylosing spondylitis (a type of inflammatory spine condition) and followed them through up to three stages. All participants received etanercept, a medicine given by injection, for 24 weeks (the "induction" period). Those whose disease activity reached a low level then had the medicine withdrawn for up to 40 weeks (the "withdrawal" period), and those whose condition worsened during that time were offered 12 weeks of retreatment. The trial was primarily measuring how many people experien...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02696798 · results posted 30 October 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 316 adults with ankylosing spondylitis (a type of inflammatory spinal arthritis). Participants were divided into three groups: 104 received a placebo (an inactive treatment), 114 received a medicine called ixekizumab every four weeks, and 98 received ixekizumab every two weeks. The trial measured how participants responded using several scoring tools that asked people to rate their pain, stiffness, fatigue, and ability to carry out daily activities — all on scales from 0 to 10, where higher numbers generally meant wor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01863732 · results posted 30 July 2019
According to the results reported on ClinicalTrials.gov, this trial involved 274 people in total across four groups. All participants had ankylosing spondylitis (a type of inflammatory spinal arthritis) and were receiving the medicine secukinumab (also called AIN457). Two groups had been on secukinumab (at either a 75 mg or 150 mg dose) from the start of the original trial, while two other groups had started on a placebo (a dummy treatment with no active ingredient) before switching to secukinumab. The trial was measuring whether improvements in symptoms held up over a long follow-up period —...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02897115 · results posted 5 July 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02897115) enrolled 22 people with ankylosing spondylitis (a type of inflammatory spinal arthritis) — 14 in a "treat-to-target" group, where treatment was actively adjusted to reach a specific disease activity goal, and 8 in a "standard of care" group, who received usual treatment without that structured target. The trial ran for 32 weeks and measured disease activity, quality of life, and the impact on work and daily activities. It is worth noting that only 3 participants in the treat-to-target group and none in the standa...
-
NCT02159053 · results posted 10 April 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02159053) enrolled 350 people in total across three groups: 116 received secukinumab 150 mg with a "loading dose" (extra doses at the start), 117 received secukinumab 150 mg without a loading dose, and 117 received a placebo (an inactive treatment). The trial was measuring how people with ankylosing spondylitis — a type of inflammatory spinal condition — responded to the medication compared to placebo, using a range of standardised questionnaires and blood tests over 16 weeks. The reported data shows that for the main out...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02407223 · results posted 13 March 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02407223) enrolled 356 people with ankylosing spondylitis (a type of inflammatory spinal arthritis) across three groups: 116 received a placebo (an inactive treatment), 118 received ustekinumab at a 45 mg dose, and 122 received ustekinumab at a 90 mg dose. The trial was measuring how participants responded to treatment at 24 weeks using several standardised scoring tools that assess things like back pain, physical function, morning stiffness, and overall disease activity. It is worth noting that the data shows no participa...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02333383 · results posted 15 January 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 201 people with a condition called ankylosing spondylitis — a type of inflammatory arthritis that mainly affects the spine. Of those who started, 160 completed the study and 41 did not finish. The trial was measuring how often participants experienced certain joint-related complications alongside their spinal condition, specifically: swelling in joints outside the spine (peripheral arthritis), tenderness where tendons or ligaments attach to bone (enthesitis), and swelling of fingers or toes (dactylitis). Participants...
-
NCT02438787 · results posted 1 October 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT02438787) enrolled 315 people with ankylosing spondylitis (a type of inflammatory spinal arthritis) across three groups: 104 received a placebo (an inactive treatment), 106 received ustekinumab at a 45 mg dose, and 105 received ustekinumab at a 90 mg dose. The main thing the trial was measuring was whether participants reached a defined level of improvement in their symptoms — including back pain, physical function, and inflammation — by week 24. A number of secondary measures looked at different ways of scoring disease ac...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02186873 · results posted 13 November 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT02186873) enrolled 208 people in total — 103 in a group that started on a placebo (a dummy treatment) before switching to golimumab, and 105 in a group that received golimumab from the start. The trial was measuring responses in people with a form of spinal arthritis, looking at whether their symptoms — including back pain, stiffness, fatigue, and ability to carry out daily activities — changed over 16 weeks. By the end of the study, 94 participants in the placebo-then-golimumab group and 97 in the golimumab group had comp...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01061723 · results posted 8 August 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT01061723) enrolled 301 people with ankylosing spondylitis (a type of inflammatory spinal arthritis) across six groups. Fifty or so participants were assigned to each group: one group received a placebo (a dummy injection with no active medicine), and the other five received different doses and dosing schedules of a medicine called sarilumab. The trial ran for 12 weeks and was mainly measuring how many participants experienced a meaningful improvement in their symptoms — specifically a 20% reduction in scores across several...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01118728 · results posted 21 June 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 223 people with ankylosing spondylitis (a type of inflammatory back condition) who received a medicine called sarilumab. The trial was measuring two main things: first, how many participants experienced unwanted medical events (called adverse events) during treatment; and second, how many participants showed a meaningful improvement in their symptoms according to a standard scoring system used in ankylosing spondylitis research. It is noted in the data that none of the 223 participants were recorded as having "complet...
-
NCT01668004 · results posted 3 August 2016
According to the results reported on ClinicalTrials.gov, this trial (NCT01668004) enrolled 101 adults with ankylosing spondylitis (a type of inflammatory spinal condition) who were given a medication called golimumab (GLM) at a dose of 50 mg. Of the 101 people who started and received treatment, 76 completed the study and 25 did not finish. The trial was mainly looking at whether the rate of a painful eye inflammation called uveitis — a known complication of ankylosing spondylitis — changed after people started golimumab, comparing the year before treatment to the year after. It also looked at...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01091675 · results posted 10 June 2015
According to the results reported on ClinicalTrials.gov, this trial (NCT01091675) involved 57 people who were given a medicine called etoricoxib. The trial was looking at a condition called Ankylosing Spondylitis — a type of inflammatory arthritis that mainly affects the spine. Of the 57 people who started the trial, 23 completed it and 34 did not finish. The main thing the trial set out to measure was how many participants met a specific set of response criteria known as ASAS criteria. To assess this, researchers used a scoring tool called the BASDAI (Bath Ankylosing Spondylitis Disease Acti...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01583374 · results posted 17 March 2015
According to the results reported on ClinicalTrials.gov, this trial (NCT01583374) looked at a medicine called apremilast in people with ankylosing spondylitis, a type of inflammatory arthritis affecting the spine. A total of 490 people took part in the first phase of the trial, split across three groups: 164 received a placebo (a dummy pill with no active ingredient), 163 received apremilast at a lower dose (20 mg), and 163 received apremilast at a higher dose (30 mg). The main thing the trial was measuring was how many people in each group showed a meaningful improvement — at least 20% better...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01209702 · results posted 11 February 2013
According to the results reported on ClinicalTrials.gov, this trial (NCT01209702) involved people with ankylosing spondylitis — a type of inflammatory arthritis mainly affecting the spine. A total of 306 participants took part across two parts of the study. In Part 1, 51 people received a placebo (an inactive treatment) and 51 received tocilizumab. In Part 2, 51 received a placebo and 153 received tocilizumab. The trial was measuring whether tocilizumab led to meaningful improvements in participants' symptoms, including pain, physical function, morning stiffness, and their overall sense of how...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01209689 · results posted 17 January 2013
According to the results reported on ClinicalTrials.gov, this trial (NCT01209689) enrolled 113 people in total — 91 received the medicine tocilizumab (at a dose of either 4 or 8 mg/kg) and 22 received a placebo (a dummy treatment with no active ingredient). The trial was investigating a condition called ankylosing spondylitis, a form of inflammatory arthritis affecting the spine. The main thing the trial set out to measure was how many participants in each group met a specific improvement threshold — known as ASAS20 — by week 12. This threshold counted someone as a "responder" if they reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00247962 · results posted 8 November 2012
According to the results reported on ClinicalTrials.gov, this trial enrolled 566 people with ankylosing spondylitis (a type of inflammatory arthritis that mainly affects the spine). Participants were split into two groups: 379 received etanercept and 187 received sulphasalazine, both existing medicines used for this condition. The trial's main goal was to measure how many people in each group achieved a recognised level of symptom improvement, known as "ASAS 20" — meaning at least a 20% improvement across key areas such as pain, physical function, and overall disease activity, rated on a 0–100...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00939003 · results posted 6 March 2012
According to the results reported on ClinicalTrials.gov, this trial enrolled 192 people in total — 97 received a placebo (an inactive dummy treatment) and 95 received adalimumab, a medication being studied for a type of inflammatory back condition. The trial had two stages: a blinded phase where neither participants nor researchers knew who was receiving which treatment, followed by an open-label phase where everyone received the active medication. The main thing the trial measured was how many participants reached a level of improvement called "ASAS40" — meaning they showed at least a 40% imp...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01114880 · results posted 4 November 2011
According to the results reported on ClinicalTrials.gov, this trial enrolled 344 people in total — 229 received adalimumab and 115 received a placebo (an inactive treatment used for comparison). The trial was looking at a condition involving inflammatory back pain, and it ran in two back-to-back periods: the first 12 weeks, then a further 12 weeks through to week 24. The main thing the trial was measuring was how many participants met a set of pre-defined response criteria — known as ASAS20 — which required a person to show at least a 20% improvement across several areas including their own ra...
-
NCT00762463 · results posted 23 August 2011
According to the results reported on ClinicalTrials.gov, this trial involved people with Ankylosing Spondylitis — a type of inflammatory arthritis mainly affecting the spine. A total of 240 participants were enrolled at the start, split evenly between two groups: 120 took celecoxib 200 mg and 120 took diclofenac SR 75 mg daily. This first part of the trial ran for 6 weeks. After that, participants who were still in the study could enter a 6-week extension phase, where some were switched to a higher dose of celecoxib 400 mg. The trial's main focus was measuring how participants themselves rated...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00085644 · results posted 11 March 2010
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called adalimumab in people with ankylosing spondylitis, a type of inflammatory back condition. The trial had two stages: a blinded phase (where neither doctors nor participants knew who received the real medicine or a dummy treatment) and a later open-label phase (where everyone received adalimumab). In the blinded phase, 208 people received adalimumab and 107 received the placebo (dummy treatment). In the open-label phase that followed, 311 participants received adalimumab, and 202 of those completed it....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, research into Ankylosing Spondylitis is currently receiving a moderate amount of public funding from the United States government, and encouragingly, that funding has been rising year on year. This upward trend suggests that scientific interest in the condition is growing, which can be a good sign for patients hoping that new approaches will be explored over time. Ri...
See the full Ankylosing Spondylitis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.